ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

The company now has RayzeBio's pipeline, including its late-stage targeted radiopharma therapy, RYZ101, for gastroenteropancreatic neuroendocrine tumors. It is also in a phase one trial for small ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Targeted radionuclide therapy, another type of systemic radiation therapy, can treat advanced prostate cancer or gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Sometimes your doctor can ...

The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Currently, her areas of focus include the development of novel theranostic agents for pancreatic cancers and understanding the role of Notch signaling in gastroenteropancreatic neuroendocrine tumors.

NSCLC = non-small cell lung cancer; CUP = carcinoma of unknown primary; CCC = cholangiocarcinoma; GEP-NET= Gastroenteropancreatic neuroendocrine tumor. Image created with contributions from ...

LUTATHERA® is the first and only approved radiation treatment for adults with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) that can grow in the pancreas or other areas of the stomach ...